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Introduction: Radiographic density adversely affects the performance of X-ray mammography and can be
particularly problematic in younger and high-risk women. Because of this limitation, there is significant ongoing
effort to develop alternative cancer screening and detection strategies for this population. This pilot study evaluates
the potential of Diffuse Optical Spectroscopic Imaging (DOSI) to image known tumors in dense breast tissue.
Methods: We performed a retrospective analysis on 24 radiographically dense breast cancer subjects measured
with DOSI over a four-year period (Breast Imaging Reporting and Data System - BI-RADS, category 3 and 4, average
age = 39 ± 7.6, average maximum size 31 ± 17 mm). Two previously-described DOSI contrast functions, the tissue optical
index (TOI) and the specific tumor component (STC), which are based upon the concentrations and spectral signatures of
hemoglobin, water and lipids, respectively, were used to form 2D optical images of breast tumors.
Results: Using TOI and STC, 21 out of 24 breast tumors were found to be statistically different from the surrounding
highly vascularized dense tissue and to be distinguishable from the areolar region. For these patients, the tumor to
normal contrast was 2.6 ± 1.2 (range 1.3 to 5.5) and 10.0 ± 7.5 (range 3.3 to 26.4) for TOI and STC, respectively. STC
images were particularly useful in eliminating metabolic background from the retroareolar region which led to
identification of two out of four retroareolar tumors.
Conclusions: Using both the abundance and the disposition of the tissue chromophores recovered from the DOSI
measurements, we were able to observe tumor contrast relative to dense breast tissue. These preliminary results suggest
that DOSI spectral characterization strategies may provide new information content that could help imaging breast
tumors in radiographically dense tissue and in particular in the areolar complex.Introduction
Tumors and glandular tissue have a similar dense appear-
ance on mammography, making it difficult to distinguish
metabolically active normal breast tissue from cancer. As
a result, the performance of mammography in women
with high breast density is poor [1,2]. While the overall
sensitivity of mammography is about 75% and can be as
high as about 90% in postmenopausal fatty breasts, it
drastically drops to about 50% and 30% in women with
heterogeneous and extremely dense breasts, respectively
[3-5]. Younger and high-risk women who tend to have
denser breasts are particularly impacted by this limitation.* Correspondence: bjtrombe@uci.edu
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reproduction in any medium, provided the orGiven these difficulties, there are conflicting opinions re-
garding the use of mammography. The National Cancer
Control Network (NCCN) recommends annual screening
for women over 40, while the U.S. Preventative Services
Task Force concluded that the risk of false positives and
complications from biopsies is too high for screening
mammography in pre- and peri-menopausal women, that
is, up to age 50 [6]. Although the risk of breast cancer is
low in this population, women in their 40s account for at
least a quarter of breast cancer diagnoses and up to 17%
of breast cancer deaths each year [6]. The National Cancer
Institute estimates that up to 20% of all breast cancers,
roughly 40,000/year in the U.S., are not discovered by
screening mammography. Moreover, breast cancer at a
young age tends to be more aggressive and less likely to
respond to treatment as compared to breast cancer inl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tection of breast cancer in women with dense breast tissue.
Detection and characterization of tumors in dense breasts
have been investigated using several alternative approaches,
such as magnetic resonance imaging (MRI), ultrasonography
(UN), digital mammography and positron emission tomog-
raphy (PET) [4,8-14]. Digital mammography has been
shown to have better tumor detectability in dense breasts
[13] compared to older film-based systems. The overall de-
tection rate, however, is still moderate in younger and high-
risk subjects [4]. Previous studies have shown that adding
screening ultrasound to mammography can improve over-
all performance in dense breasts [4,8,11], and that breast
MRI is generally not limited by breast density [12]. How-
ever, there are concerns that the use of both MRI and US
may increase false positive rates. Breast-dedicated PET has
been shown not to be independent of breast density and to
have a better specificity than MRI [14]. However, PET relies
on the injection of a radioactive tracer in the patient’s body.
Optical imaging has been predicted to improve sensitivity
and specificity in dense breast tissues, but this has not yet
been well established. Most published optical studies focus-
ing on lesion detection and characterization were performed
in heterogeneous breast density populations [15-21]. In-
creased hemoglobin and water content, as well as decreased
lipid content were observed in tumors compared to normal
surrounding breast tissue. Most studies have shown that
tumor contrast in hemoglobin concentration is the strongest
detection marker of tumors [22]. Mammographically dense
breast tissue also contains higher hemoglobin content, as a
result of the increased metabolic activity of fibro-glandular
tissues with respect to fatty breast tissue. This can minimize
the tumor to normal hemoglobin contrast limiting the ef-
fectiveness of Diffuse Optical Spectroscopic Imaging (DOSI)
and related optical imaging techniques to identify tumors in
dense breasts. There are few optical imaging studies that
have examined mammographically dense breast tissue. For
example, Taroni et al. proposed an optical index that corre-
lates with mammographic density [23]. This index is de-
rived from water, collagen and lipid content, combined with
a tissue scattering parameter, and is measured using time-
resolved transmittance spectroscopy. Blackmore et al. and
Blyschak et al. investigated the correlation between mam-
mographic density and optical transillumination spectros-
copy [24,25]. The objective of these studies was to assess
breast density as an indicator for breast cancer risk. To our
knowledge, the visualization, detection or characterization of
tumors in dense breast tissue has never been investigated
using optical techniques.
In this paper, we present a pilot study that prospectively
assesses the potential of DOSI to image breast cancer in 24
patients with dense parenchymal tissue of Breast Imaging
Reporting and Data System (BI-RADS) 3 and 4 using two
relatively new contrast functions. DOSI measures breasttissue physiological properties and composition (for ex-
ample, tissue concentration of oxy- and deoxyhemoglobin,
water and lipid). The DOSI method employed in this study
is based on mapping tissue absorption and scattering spec-
tra (650 to 1,000 nm) [26] acquired using a hand-held
probe scanned over approximately 50 to 100 discrete loca-
tions on the breast for each subject. A tissue optical index
(TOI) that is sensitive to the metabolic activity of breast tis-
sue can be derived from these physiological properties
[17]. Moreover, using a double differential spectroscopy
technique, signatures of specific tumor components (STC)
can be obtained. The STC is based on detecting small
spectral shifts that are hypothesized to be related to the
unique disposition of chromophores present in malignant
tumors but not in normal or benign tissues [27]. Our
results suggest that there is complementary informa-
tion from TOI and STC regarding tissue breast tissue me-
tabolism and composition. Together, these contrast
functions were able to significantly discriminate 21 out
of 24 breast tumors from highly vascularized dense tis-
sue. These preliminary findings support the idea that
DOSI spectral characterization strategies may provide
new information content that could potentially support
breast cancer detection in radiographically dense tissue.
Methods
DOSI instrument
A description of the basic components of our DOSI instru-
ment has been previously presented [28,29]. Briefly, DOSI
consists of a combined frequency-domain photon migration
(FDPM) component and a broadband steady-state (SS)
component integrated together to produce broadband ab-
sorption and scattering spectra of tissues from 650 to 1,000
nm. The FDPM component uses six laser diodes (Blue Sky
Research, Sanyo, Mitsubishi, Japan) at the wavelengths 658,
682, 785, 810, 830 and 850 nm. The breast is illuminated se-
quentially by each laser diode, which is intensity-modulated
at 401 modulation frequencies swept from 50 to 600 MHz.
The back-scattered light is detected by an avalanche photo-
diode (Hamamatsu model C5658 module, customized with
S6045-03 APD, Hamamatsu Photonics K.K., Solid State Div-
ision, 1126-1 Ichino-cho, Higashi-ku, Hamamatsu City 435-
8558, JAPAN) mounted inside a hand-held probe. The SS
component uses a high-intensity tungsten-halogen source
(Mikropack model HL-2000-HP-FHSA, Ocean Optics, Inc.,
830 Douglas Ave, Dunedin, FL 34698, USA) to illuminate
the tissue and the back-scattered light is detected by a
grating-based spectrometer (650 to 1,000 nm, 1,024 pixels,
BWTek model 611E, B&W Tek, Inc., 19 Shea Way, New-
ark, DE 19713, USA). The FDPM and SS sources are
coupled by optical fibers mounted into the hand-held probe.
The separation between source and detector fibers was 28
mm for both FDPM and SS with fibers placed in an overlap-
ping geometry [17].
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absorption (μa) and reduced scattering (μs’) spectra from
650 to 1,000 nm. In the FDPM measurement, the phase and
amplitude of the remitted light are recorded as functions of
modulation frequency and fit to a diffusive model of light
transport (semi-infinite boundary conditions) to recover μa
and μs’ at each of the six laser wavelengths. SS broadband
spectra were converted into absolute absorption spectra
using two simple steps. First, the spectral shape of the re-
duced scattering spectrum is assumed to follow a power law
of the form μs’ = Aμ-sp, where A is the scatter amplitude
and sp is the scatter power, or the exponent of the scattering
spectrum. The power-law fit to the FDPM discrete laser
diode spectrum provides a scatter correction for the SS re-
flectance spectrum. We then fit the SS reflectance intensity
at each of the laser diode wavelengths to the reflectance cal-
culated from the FDPM-measured absolute absorption
values. Thus, the SS reflectance spectrum intensity is scaled
using the FDPM discrete laser diode measurements. The ab-
solute absorption spectrum is then extracted by fitting the
corrected reflectance spectrum to a diffusion reflectance
model [29,30].
Spectral analysis
Spectral analysis is performed on the absorption data assum-
ing that the absorption in normal breast is caused mainly by
the tissue concentration (ct) of four main chromophores:
deoxyhemoglobin (ctHHb), oxyhemoglobin (ctO2Hb), water
(ctH2O) and bulk lipid. We recover these chromophore con-
centrations by fitting a linear combination of their basis mo-
lecular extinction coefficient spectra to the scatter-corrected
absorption spectrum [31]. ATOI representative of tissue me-
tabolism has been introduced previously [17]: TOI = ctHHb
x ctH2O/lipid. The TOI is typically used to identify the func-
tional/spatial extent of the lesion [17,32] and areola.
The STC is determined by taking the difference between
sample (that is, tumor) and reference (that is, healthy) tissue
absorption spectra and analyzing the residuals of the fit of
this first differential to the four-component basis chromo-
phores of breast tissue. Details of this method have been
reported [33,34]. Briefly, the first differential (between tumor
and healthy tissue absorption spectra tissue) provides a
spectrum that removes spectral components common to
both tissues. The second differential (between the aforemen-
tioned first differential and its fit to the four-chromophore
basis spectra) provides a spectrum containing the additional
contributions of chromophores not accounted in this fit.
This second differential fit is not to be confused with “second
derivative spectroscopy” where derivatives of the measured
intensity are fit to derivatives of the basis chromophore spec-
tra to obtain concentrations of the basis components. Ra-
ther, localized subtle spectral features not described by the
basis spectra are detected by fitting differences in absorp-
tion to the basis spectra of oxy- and deoxyhemoglobin,water and lipid in one molecular state. Thus, the residual
of the chromophore fit to the first differential, known as
the STC spectrum, emphasizes the contributions of other
chromophores not accounted in the basis spectra fit (for
example, met-hemoglobin), and contains information on
shifts of water and lipid peaks that correlate with different
molecular states that differ between the sample and refer-
ence locations.
In order to quantify the STC spectrum, an STC index
was defined by the sum of all local residual variances Lk
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The local variance Lk is a function of the position on the
breast given by x and y coordinates. The index k indicates
a given spectral region and Nk indicates the total number
of wavelengths in the spectral region. STCi(λi, x, y) is the
value of the STC spectra at a given wavelength. The spec-
tral regions are as follows: 650 to 665 nm, 730 to 800 nm,
875 to 930 nm, 930 to 960 nm and 980 to 990 nm. These
five regions have been defined empirically to maximize the
differences between tumor and normal [33].
Using the TOI and STC index for each spatial measure-
ment point of the breast (see below for measurement de-
scription), TOI and STC index maps can be obtained [34].
Breast density
Breast density is often expressed using the BI-RADS.
The BI-RADS classification system defines four categories
for breast density, qualitatively based on the relative
amounts of fat and dense fibroglandular tissue observed
in a mammogram. BI-RADS 1 refers to almost entirely
fatty tissue; BI-RADS 2 refers to scattered fibroglandular
densities that could potentially obscure a lesion; BI-RADS
3 refers to a heterogeneously dense breast type and the
sensitivity of mammography may be lowered; BI-RADS 4
refers to an extremely dense breast type that will lower
the sensitivity of mammography [1].
Subject selection and measurement procedure
A retrospective analysis was conducted on 24 breast cancer
subjects (average age = 39 ± 7.6, range 25 to 50) who were
measured with DOSI between 2007 and 2011 and met the
criteria of breast tumors and dense breast tissue BI-RADS
3 and 4. Subject information is shown in Additional file 1.
Lesion pathology was determined by core biopsy: the
study included 17 invasive ductal carcinomas (IDC), 5
invasive lobular carcinomas (ILC) and 2 ductal carcinomas
in situ (DCIS). Breast density was determined from mam-
mography: 16 subjects had extremely dense breast tissue
(BI-RADS 4), 7 subjects had heterogeneously dense breast
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not available for one subject: this subject was included in
the study as her tumor was retroareolar and was not
visible in mammography. Out of these 24 subjects, 21
were premenopausal, 2 were perimenopausal and 1 was
postmenopausal. The lesion sizes and locations were
determined by ultrasound examination and ranged from 8
to 70 mm with an average maximum size of 31 ± 17 mm.
All subjects provided informed written consent under
protocols approved by Institutional Review Board of the
University of California, Irvine.
DOSI measurements were performed using a standard
protocol [32]. The normal contralateral breast of five
subjects was not measured with DOSI, though ipsilateral
normal tissue was measured for all subjects. All subjects
were measured in a supine position. The DOSI probe
was placed against the breast tissue, and sequential mea-
surements were taken in a rectangular grid pattern using
10-mm spacing. Broadband absorption and reduced scat-
tering spectra (650 to 1,000 nm) were measured at each
location. The dimension of the grids ranged from 3 x 9 to
10 x 9 cm2 for the normal contralateral breast and from
5 x 9 to 13 x 13 cm2 for the ipsilateral breast. For better
visualization, the DOSI images presented in this paper
are interpolated images.
Data analysis
The areola was included, partly or entirely, in the field of
view of the DOSI images in 20 out of the 24 subjects.
For data analysis, the areolar regions were defined in the
TOI images and on the actual physical size of the areola.
The tumor region was defined around the peak values in
the TOI and STC index images and using the tumor size
given by the ultrasound examination. The normal tissue
in the ipsilateral breast was defined as the field of view
excluding the tumor and areola regions and an additional
1 cm wide zone around these regions. The tumor to
normal (T/N) contrast was defined by the average value in
the tumor region divided by the average value in the
background normal tissue region [35].
In the box plots presented in this paper, the box
represents the standard deviation and median of the
depicted values, the bar represents the total range
(minimum to maximum), and the square represents the
average value.
In the DOSI images, we refer to as “Cancelled Areolas”
the areola regions for which the DOSI signal is found
statistically lower than the signal from the tumor. Visually,
this corresponds to a highly attenuated signal at the areola
regions in the DOSI image due to the STC spectral pro-
cessing. Otherwise, we refer to the cases as “Not Cancelled
Areola”. We expect better identification of tumors in the
cases of “Cancelled Areola” as the areolar signal does not
obscure the signal from the tumor.Consent section
Written informed consent was obtained from the patients
for publication of this manuscript and accompanying im-
ages. Copies of the written consents are available for review
by the Editor-in-Chief of this journal.
Statistical analysis
Statistical significance between the two groups was
performed using a one-tailed Wilcoxon test at alpha = 0.05.
The statistical significance between tumor and normal
dense tissue was established in the TOI and STC index
images of each patient in several steps. First, the statistical
significance of the difference between tumor and normal
tissue, as defined in the Data analysis section, was assessed
for both the STC and TOI datasets of each patient. Then,
for the subset of STC and TOI data exhibiting statistical
significance, we rejected the cases of missed tumors, which
we defined as cases where the signal from the normal tissue
was greater than from tumor tissue. For this resulting
subset of data, we determined the statistical signifi-
cance between tumor and areola regions in the case of
areolar tumors. Two areolar tumors that were not visu-
ally separated from the areola were also excluded from
the analysis. The number of STC and TOI datasets
exhibiting statistical difference between tumor and normal
dense breast tissue were based upon the final resulting
datasets of this process.
Results
We depict in Figure 1 the DOSI measurement process
of patient #3, a 39-year-old premenopausal female with
a 21 mm IDC in the upper outer part of her left breast.
Figure 1A presents the left craniocaudal view of the
mammogram of this patient. She was assessed with
BI-RADS 3 mammographic density. The arrow points at
the tumor location. Figure 1B illustrates the 60 x 60 mm2
DOSI measurement grid performed on this patient relative
to the tumor position and size, and areola. Figure 1C shows
the scatter-corrected absorption spectra of a tumor lo-
cation (dotted line) and a normal healthy tissue location
(solid line) of this breast. The lesion has a substantially
higher absorption than the normal breast tissue with
elevated hemoglobin (mainly 650 to 850 nm) and water
(mainly 950 to 1,000 nm) [17]. Figure 1D presents the
resulting TOI image of this measurement; note that this
image is not normalized. An area with increased TOI value
is observed and corresponds to the tumor location known
from ultrasound. Figure 1E presents the STC spectra of the
same tumor and normal tissue locations as shown in
Figure 1C. The tumor STC spectrum (dashed line) contains
greater peaks in absolute value in the hemoglobin region
and in the water region as compared to the normal tissue
STC spectrum (solid line) [27]. This can be interpreted as
the tumor region having greater malignant components
Figure 1 DOSI measurement with typical recovered absorption and STC spectra in tumor and normal tissue. A) Mammogram, left
craniocaudal view, of a 39-year-old female subject with a 21 mm IDC in the left breast with a BI-RADS 3 density. The arrow points at the tumor.
B) Schematic of the DOSI measurement grid for this subject. DOSI measurement locations are 10 mm apart in x and y directions. For this subject,
the 60 x 60 mm2 grid covers the lesion and some normal tissue. C) Absorption spectra in lesion (dotted line), and background (solid line). D) TOI
map. E) STC spectra in lesion (dotted line), and background (solid line). F) STC index map. Increased TOI and STC index values are found in the
tumor area, highlighted with the dash line circle. BI-RADS, Breast Imaging Reporting and Data System; DOSI, Diffuse Optical Spectroscopic
Imaging; IDC, Invasive ductal carcinomas; STC, Specific tumor component; TOI, Tissue optical index.
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the corresponding STC index image of this measure-
ment. An increased STC index value is observed in the
tumor region [36]. Note that the TOI and STC index maps
are top-down views.
Figure 2 illustrates a challenging case confounded by
the dense areola tissue. The subject is a 49-year-old
premenopausal female with IDC in the upper outer quad-
rant of the left breast and with a breast density of BI-RADS
4 (Patient #5). Figure 2A shows the mammogram of theipsilateral breast of this subject in the medio-craniocaudal
view. Figure 2B shows the schematic representation of the
DOSI measurement. Figure 2C, D presents the TOI and
STC index images of the ipsilateral breast, respectively, and
Figure 2G, H presents the TOI and STC index images of
the normal breast, respectively. In Figure 2C, we observe a
global increase in TOI value in the whole field of view.
However, the tumor (dashed line) shows the highest TOI
values. The TOI variations observed around the tumor and
areola (solid line) regions are most probably due to normal
Figure 2 DOSI results of subject #5, IDC in the left breast, breast density BI-RADS 4. (A) Mammogram, left medio-craniocaudal view. The arrow
highlights the tumor location. (B) Schematic representation of the DOSI measurement in the ipsilateral breast. (C) TOI map of the ipsilateral breast.
(D) STC index map of the ipsilateral breast. (E) TOI values in tumor, areola and normal tissue of the ipsilateral breast. (F) STC index values in tumor,
areola and normal tissue of the ipsilateral breast. (G) TOI map of the contralateral breast. (H) STC index map of the contralateral breast. The square
represents the nipple location. The areolas are highlighted with the solid line circle, and the tumor by the dash line circle. BI-RADS, Breast Imaging
Reporting and Data System; DOSI, Diffuse Optical Spectroscopic Imaging; STC, Specific tumor component; TOI, Tissue optical index.
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enhancements from the tumor and glandular tissue are
connected, this tumor is difficult to observe in the TOI
image. In Figure 2D, we observe an increase in STC index
value mainly in the tumor region. TOI fluctuations are also
present in the background but are negligible compared to
the signal from the lesion. Note that there is insufficient
contrast in the STC index map to reveal the areola.
Figure 2E, F show the box plots of the TOI and STC
index values of tumor, areola and normal tissue in the
ipsilateral breast. As visually observed in Figure 2C,
the highest TOI values are found in the tumor, but the
areola and normal background tissue also exhibit high
TOI values. Figure 2F shows that the STC signal from the
tumor is dominant over the normal dense breast tissue
including the areola, as visually observed in Figure 2D.
Figure 2G, H shows the TOI and STC index maps, re-
spectively, of the contralateral breast of this subject.
The areola region and glandular tissue are again mainly
observed in the TOI image.
We present in Figure 3 a more challenging case of a
retroaerolar lesion not detected by mammography. This
subject (patient #17) is a 42-year-old postmenopausal
female with a 23 mm retroareolar IDC at 6 to 7 o’clock in
the right breast. Figure 3A presents the mammogram of
this breast in the craniocaudal view, and Figure 3B shows
the DOSI measurement configuration. In Figure 3C, we
observe a general increase of TOI in an extended region
of the areola (the boundary of the areola is depicted by the
solid line). The lesion, highlighted by the dashed line, can-
not reliably be discriminated from the areola in this TOI
map. In Figure 3D, we observe an increase in STC index
value in the tumor region, which is overlaid by the areola
region. Figure 3E, F presents the box plots of the TOI and
STC index values of tumor, areola and normal tissue in
the ipsilateral breast. In these plots, the areola region
excludes the area of the tumor. In Figure 3E, the peak
TOI value is observed at the tumor location, but both the
areola and the tumor have similar TOI values, and the
areola and tumor cannot be spatially separated. The plot
in Figure 3F illustrates that the STC signal from the tumor
is different from the STC signal from the areola and normal
background tissue. This difference is statistically significant
(Wilcoxon test at alpha = 0.05, P-value <0.01). Figure 3F
also shows that the STC values from background and areola
range similarly, implying that the STC contrast function
may be insensitive to breast tissue density for this patient
[34]. Figure 3G, H shows the TOI and STC index maps,
respectively, of the contralateral breast of this subject. The
areola, contained within the solid line, is observed in the
TOI map but has a very low STC index signal. The contra-
lateral STC index maps show little enhancement from the
areola, suggesting that the increased values observed in the
ipsilateral STC index are mainly due to the tumor.Table 1 reports the average (standard deviation and range)
of the mean ctO2Hb, ctHHb, H2O, lipid and TOI con-
centrations in the tumor, normal healthy breast tissue,
and areolar tissue. Elevated blood, water and TOI as
well as decreased lipid content are on average observed
in tumors and areolas compared to normal dense breast
tissue. The mean DOSI parameter differences between
tumor and normal dense tissue are all statistically signifi-
cant (Wilcoxon test at alpha = 0.05, P <0.01), while only
oxyhemoglobin is statistically different between tumor
and areolar tissue (Wilcoxon test at alpha = 0.05, P <0.01).
Figure 4 presents the normalized TOI and STC index
values for the 24 subjects in tumor, background and
areola. We observe that the background signal from
dense breast tissue is on average lower in the STC index
images than in the TOI images.
Statistically, 20 out of 24 lesions were significantly
different from the background normal tissue in the TOI
images (Wilcoxon test at alpha = 0.05, P-value <0.04)
and 22 out of 24 lesions in the STC index images
(Wilcoxon test at alpha = 0.05, P-value <0.04). For four
subjects, the signal from the tumor was statistically differ-
ent either in the TOI image or in the STC index image.
Only one lesion was found not statistically different from
the background in both the TOI and STC index images.
This lesion is a 16 mm DCIS tumor in a 25-year-old subject
with breast density of BI-RADS 4. An enhancement at the
tumor location was nevertheless observed in the TOI image
with a contrast of 1.3.
Unrelated to the statistical difference between tumor
and background normal tissue, the tumor region could
not be visually spatially separated from the areolar re-
gion in six patients in the TOI image and in two patients
in the STC index image due to the extended presence of
glandular tissue. For the tumors statistically different from
normal dense breast tissue and spatially indistinguishable
from the areola, the mean T/N contrast was 2.6 ± 1.2
(range 1.3 to 5.5) and 10.0 ± 7.5 (range 3.3 to 26.4) in the
TOI and STC index maps, respectively.
Among the four areolar lesions, two were not discrimi-
nated from the areola in both the TOI and STC index
images. In one subject, the lesion was separated from
the areola in both the TOI and STC index images. In the
last subject, shown in Figure 3, the lesion could not be
distinguished from the areola in the TOI image, but was
clearly resolved from the areola in the STC index image.
We observed an attenuated STC signal from the glandular
tissue including the areolar region in 11 subjects out of the
20 with the areola in the field of view, as seen for instance
in patients presented in Figures 2 and 3.
Discussion
Using the TOI and STC index, 21 out of 24 breast tumors
were found to be statistically different from the surrounding
Figure 3 DOSI results of subject #17, a 42 y.o. woman with a retroareolar 23 mm IDC. (A) Mammogram, left craniocaudal view. (B) Schematic
representation of the DOSI measurement. (C) TOI map of the ipsilateral breast. (D) STC index map of the ipsilateral breast. (E) TOI values in tumor,
areola and normal tissue of the ipsilateral breast. (F) STC index values in tumor, areola and normal tissue of the ipsilateral breast. (G) TOI map of the
contralateral breast. (H) STC index map of the contralateral breast. The square represents the nipple location. The areolas are highlighted with the solid
line circle, and the tumor by the dash line circle. IDC, Invasive ductal carcinomas; STC, Specific tumor component; TOI, Tissue optical index.
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the areolar region. Two out of the four areolar lesions were
discriminated from the areolar region in the optical images.
Drastic attenuation of the STC signal from the areola anddense breast tissue was observed in 11 out of the 20
subjects who had the areola in the field of view.
Dense breast is characterized by a relatively high fibro-
glandular-to-lipid tissue ratio compared to normal breast.
Table 1 Average and standard deviation (minimum to
maximum) of the mean chromophore values in tumor
and normal breast tissue
Tumor Normal Areola
ctO2Hb 26.8* ± 10.7 17.8 ± 4.9 20.1** ± 5.9
(9.9 to 59.1) (9.7 to 32.9) (10.7 to 33.2)
ctHHb 8.3* ± 2.1 5.4 ± 1.2 8.1† ± 3.0
(4.1 to 11.8) (3.7 to 8.5) (4.8 to 17.0)
H2O 37.9* ± 12.9 26.9 ± 10.3 45.4† ± 11.7
(17.7 to 66.5) (17.0 to 64.3) (25.1 to 76.6)
lipid 58.2* ± 11.3 65.9 ± 11.3 51.6† ± 10.6
(35.4 to 88.6) (32.4 to 95.4) (28.6 to 71.9)
TOI 6.8* ± 5.5 2.9 ± 3.4 9.5† ± 8.2
(1.3 to 25.1) (0.9 to 18.1) (1.8 to 38.0)
STC 1,968.9* ± 3,701.0 336.2 ± 900.2 935.1 ± 1,688.3
(21.3 to 16,509.9) (16.1 to 4,450.0) (21.9 to 7,085.9)
*, **, † denote a statistically significant difference (Wilcoxon test at alpha = 0.05,
P <0.01) between tumor and normal, between tumor and areola, and between
areola and normal, respectively. ctO2Hb, Concentration of oxy-hemoglobin (μM);
ctHHB, Concentration of deoxyhemoglobin (μM); STC, Specific tumor
component; TOI, Tissue optical index.
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http://breast-cancer-research.com/content/15/5/R89The tissue chromophore concentrations presented in Table 1
support this observation and agree with O’Sullivan et al.
who reported a significant difference in deoxyhemoglobin,
TOI and water between pre- and post-menopausal patients
[37]. These changes reflect the greater vascular density,
water content and metabolic activity of dense breast tissue
[38]. The elevated mean deoxyhemoglobin and water con-
tent found in highly glandular areolar tissue, (Table 1), is
also consistent with this concept.
A total of 16 out of 24 tumors were statistically different
from the background dense breast tissue and could be
distinguished from the areola region in the TOI map only.
For these 16 tumors, the TOI T/N contrast was 2.6 ± 1.2
(range 1.3 to 5.5). For comparison, the areola to normalFigure 4 Box plot of the TOI and STC index in tumor, areola and norm
tissue of the ipsilateral breast. (B) STC index values in the visible tumor, are
component; TOI, Tissue optical index.contrast in TOI was 3.1 ± 2.3 (range 1.1 to 8.4). Although
TOI contrast may exist between tumor and glandular
tissue, a high TOI signal is not exclusive to tumor and
can be observed in fibroglandular tissue. Significant in-
creases in mean hemoglobin, water and TOI, and de-
creases in mean lipids were observed in tumors relative to
normal breast tissue, see Table 1. These differences
are a direct result of tumor physiology and metabolism,
including angiogenesis, cellular proliferation (often very
high in young patients) and edema [15,17,39]. However,
mean deoxyhemoglobin, water and lipid content was com-
parable for tumor and areola regions. These results suggest
that even though contrast in TOI should be observable
between tumor and glandular tissue, the highly-dense
areolar complex may impact tumor to normal contrast.
This explains why only 16 out of the 24 tumors were
distinguishable from the normal dense breast tissue in
the TOI images.
The STC index quantifies small spectral shifts present
in the NIR absorption spectra of lesions that are believed
to be related to the unique molecular disposition of
chromophores present in malignant tumors [40,41]. STC
tumor to normal contrast is based upon the extent to
which the different molecular environment in tumor
versus healthy tissue is able to induce distortions in pure
component spectra [42,43]. As a result, the STC has spe-
cificity for malignant tumor tissue and not for normal
glandular/fibroglandular structures. The STC index is
thus less sensitive to breast density than the TOI. This
explains why STC values for 20 (versus 16 for the TOI)
out of 24 tumors were statistically different from normal
dense breast tissue and why STC index maps could be used
to identify tumors in the areolar region. The STC index
T/N contrast was 10.0 ± 7.2 (range 3.3 to 26.4), 3.8-fold
higher than TOI T/N values. For comparison, the STC
areola to normal contrast was 7.4 ± 17.9 (range 0.3 to 87.3).
Even though the absolute contrast in areola is on averageal tissue. (A) TOI values in the visible tumor, areola and normal
ola and normal tissue of the ipsilateral breast. STC, Specific tumor
Figure 5 Box plot of STC index: no contrast in 11 out of 20
areolas. STC index values in the background normal tissue, STC
Cancelled Areola, STC Not Cancelled Areola, and visible tumor.
The number of patients for each region of interest is shown
above each box. STC, Specific tumor component.
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http://breast-cancer-research.com/content/15/5/R89higher in the STC index images than in the TOI images
(7.4 versus 3.1, respectively), the mean values in the areola
relative to the tumor are lower in the STC index images
than in the TOI images (0.4 ± 0.2 and 0.2 ± 0.2, respect-
ively; see Figure 4). We also observe in Figure 4 that the
background signal from the dense normal breast tissue in
the STC index images is on average lower than the back-
ground normal signal in the TOI images (0.17 ± 0.10 and
0.06 ± 0.05, respectively). Figure 3 presents the case of an
areolar tumor that was not detected using mammography.
Even though TOI tumor to background contrast is
observed at the tumor region, the lesion cannot be
discriminated from the areola in the TOI image. The
featureless STC index map of the opposite normal breast
suggests that the STC is not sensitive to the areolar sig-
nal of this subject. As a result, we can assume that the
STC index enhancement observed in the tumor breast
(and, more specifically, at the tumor area as predicted by
ultrasound (US)) is primarily due to the tumor. Similar at-
tenuation of the areola region occurred in 11 out of 20 sub-
jects and did not correlate with BI-RADS breast density.
The areola measurements were divided into two sub-
categories according to the DOSI enhancement. In the
case of a highly attenuated DOSI signal, the areolas are
referred to as “Cancelled Areola”; otherwise, the areolas
are referred to as “Not Cancelled Areola”. We observed
1 and 11 cases of “Cancelled Areolas” in the TOI and STC
index images, respectively. The TOI case of “Cancelled
Areola” was found in a peri-menopausal woman with high
breast density (BI-RADS 4). High TOI signal is usually
seen in the areola complex of similar breast tissue type.
For this particular case, we suspect the tumor had ex-
ceptionally high metabolic activity that was driving the
unusually elevated TOI tumor values relative to normal
dense tissue. The tumor had a Tubular Nuclear Mitotic
(TNM) score of 9/9, which potentially supports this con-
jecture. Unfortunately, other specific details of the tumor
pathology, such as hormone receptor and HER2 status, or
ki67 index were not available for this patient. Figure 5
summarizes the STC index values in background normal
tissue, lesion and areola. This plot shows that the STC sig-
nal from the “Cancelled Areola” is in the same range as
the signal from the background normal tissue. In these
cases, the STC index is only sensitive to the tumor and
the dense glandular breast tissue of the areola is similar to
the background healthy tissue. Since the areolar region
contains the densest glandular tissue of the breast, this re-
sult suggests that DOSI has the potential to detect tumors
in some young and very dense breast where other imaging
modalities may fail.
The underlying reason for the cancellation of glandular
tissue in the STC index maps of only 11 out of 20 subjects
is not yet fully understood. One possibility is that the
metabolic activity occurring in the fibroglandularnormal tissue of premenopausal women may be in-
volved. Breast parenchyma is known to change
throughout the menstrual cycle. This may result in
changes for certain chromophores, such as water, in the
glandular tissue that could be misclassified as malignant tis-
sue. A modified STC index would be required to compen-
sate for these variations. Another possibility is that the
spectral bands used for the calculation of the STC index
are not optimal for tumor identification. More work is re-
quired to refine the choices of these bands to obtain an
index purely unique to malignant tumors. This should im-
prove the STC index capabilities to reliably visualize all tu-
mors in dense breast tissue by fully attenuating the signal
from glandular tissue.
While only the TOI and STC index were investigated
in this work, other combinations of variables will be
explored in future research.
The average maximum dimension of the tumors included
in this study was 31 mm (range 12 to 70 mm). It is of im-
portance to be able to also visualize smaller breast cancers.
By our protocol criteria, we measure tumors that are at
least 10 mm in the greatest dimension. In this study, we
investigated these tumors as a proof of the concept that
DOSI contrast could be obtained in tumors located in
dense breasts. The impact of tumor depth was also not
addressed in this work because the DOSI probe incorpo-
rated a single imaging view. We expect that some of the
results presented in this study may vary depending upon
tumor depth and size. However, we suspect that the STC
signal is less susceptible to depth dependent variation than
the TOI. This is due to the fact that STC contrast is highly
sensitive to small differences in normalized spectral fea-
tures while TOI contrast is based on absolute differences
in T/N spectral amplitudes.
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http://breast-cancer-research.com/content/15/5/R89Conclusion
In summary, the high spectral content of DOSI measure-
ments can be used to create complementary contrast func-
tions based on the abundance and disposition of intrinsic
tissue chromophores. These features may be useful in tumor
detection and diagnosis in difficult to access dense breast re-
gions, such as the areolar complex and other highly
vascularized, metabolically active glandular structures.
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